Novo Nordisk erweitert sein Geschäftsfeld Wachstumsstörungen mit dem Erwerb der nordamerikanischen Rechte an Macrilen ™, das erste und einzige von der FDA zugelassene Produkt zur Diagnose von Wachstumshormonmangel bei Erwachsenen
Aeterna Zentaris is up 20.69% in midday trading to $2.80. Shares opened today at $2.32. The company has a 52-week low of $1.29 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $5.50, marking a 137.07% potential upside from current levels. In a report issued on May 21, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on AEZS, with a price target of $5.50, which implies an upside of 137% from current levels.